Evathera
Five-year NIH-funded program supports preclinical research, drug product manufacturing, regulatory preparation, and planned clinical studies, advancing MTTI’s EvaThera™ platform and oncology pipeline.
Industry Recognition Highlights EvaThera™ as a Next-Generation Pharmacokinetic Engineering Platform for Precision Radiopharmaceutical Therapy
Largest Reported Clinical Dataset for an Albumin-Binding Radiotherapeutic Supports the Evans Blue Platform as a Foundational Technology for Next-Generation Targeted Radiopharmaceuticals
FOR IMMEDIATE RELEASE
WEST CHESTER, Pa.–(BUSINESS WIRE)–Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, today announced updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE), following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
The 81-patient experience represents one of the largest clinical datasets reported to date for an albumin-binding peptide receptor radionuclide therapy (PRRT) and provides growing evidence that EBTATE may offer a differentiated and potentially best-in-class profile compared with conventional PRRT approaches.
The findings further validate MTTI’s proprietary Evans Blue (EB) technology platform, which utilizes reversible albumin binding to extend circulation time, enhance tumor uptake, and increase tumor retention. Preclinical studies have demonstrated up to 26-fold higher tumor retention compared with conventional radiopharmaceutical approaches, supporting broad applicability across multiple radionuclides, targeting vectors, and tumor types.
“The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform,” said Chris Pak, Chairman and Chief Executive Officer of MTTI. “By improving tumor delivery and retention while requiring only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential to enhance the therapeutic index of radiopharmaceuticals across multiple cancers and with both beta- and alpha-emitting radionuclides. The combination of enhanced tumor uptake, prolonged tumor retention, favorable clinical responses, and robust safety observations supports the continued development of EBTATE and highlights the broader potential of the Evans Blue platform to improve targeted radiotherapeutics across a wide range of solid tumors.”
“EBTATE achieved markedly higher tumor uptake and longer tumor retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile,” said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center and recipient of the 2026 Castle Connolly America’s Top Doctor Award. “The ability to deliver higher radiation doses to tumors with significantly lower administered radioactivity highlights the potential of this albumin-binding approach to improve the therapeutic index of PRRT. This data from NET patients supports continued clinical development and further evaluation of a streamlined treatment regimen.”
Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics for cancer. Powered by its proprietary Evans Blue (EB) technology platform, MTTI is advancing a pipeline of beta- and alpha-emitting radiopharmaceuticals designed to improve tumor targeting, increase therapeutic index, and enhance treatment efficiency. In addition to EBTATE, MTTI is developing 225Ac-EBTATE for small cell lung cancer, where preclinical studies have demonstrated comparable efficacy to 225Ac-DOTATATE at approximately 40% of the administered dose.
For more information, visit www.mtarget.com.
This press release contains forward-looking statements regarding the potential safety, efficacy, clinical benefits, development plans, and commercial opportunities of EBTATE and MTTI’s Evans Blue technology platform. Actual results may differ materially from those indicated by such forward-looking statements. EBTATE is an investigational product candidate that has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
Contacts
Chris Pak
Chairman and Chief Executive Officer
Molecular Targeting Technologies, Inc.
cpak@mtarget.com
FOR IMMEDIATE RELEASE
West Chester, PA (Business Wire) – May 28, 2026 – Molecular Targeting Technologies, Inc. (MTTI) announced the clinical findings of the Next-Generation PRRT, ¹⁷⁷Lu-DOTA-EB-TATE to treat GEP-NET Patients. The Phase 1 dose-escalation and dosimetry study will be presented at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place May 29–June 3, 2026, in Los Angeles, California.
Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies like Peptide Receptor Radionuclide Therapy (PRRT). While 177Lu-DOTATATE has demonstrated efficacy, its rapid clearance limits tumor radiation delivery and may increase renal toxicity risk.
“Our Clinical findings suggest that EBTATE may achieve meaningful clinical responses after only two treatment cycles while delivering approximately 12.5% of the cumulative radioactivity required for standard PRRT,” said Chris Pak, Chairman and Chief Executive Officer of MTTI. “If validated in larger studies, EBTATE could represent a transformative advance in radiopharmaceutical therapy, shortening treatment duration, reducing radiation exposure, and enabling physicians to evaluate efficacy much earlier than is possible today.”
“EBTATE achieved substantially higher tumor uptake and prolonged retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile, with no kidney toxicity observed for one year follow-up,” said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center. “The ability to deliver greater tumor radiation with significantly less administered radioactivity positions EBTATE as a potentially transformative PRRT. These data also support the possibility of a streamlined two-cycle regimen, enabling earlier evaluation of treatment efficacy.”
The presentation entitled, “Next-Generation PRRT” by Dr. Bodei (poster # 261874). The poster has also been selected for a 10-minute oral presentation during the 2026 Patient Education Day NETS Program Schedule (https://snmmi.org/Web/Education-and-Meetings/Patient_Education_Day_2026_NET.aspx), on 5/31/26 during the SNMMI meeting.
MTTI will present its proprietary Evans Blue (EB) albumin-binding technology platform at Booth #1758 during the SNMMI Annual Meeting, featuring clinical data from 81 GEP-NET patients and compelling preclinical results.
MTTI’s EB technology enhances tumor targeting through reversible albumin binding, delivering up to 26-fold greater tumor retention in preclinical models and approximately eight-fold higher tumor uptake in patients compared with conventional DOTA-TATE. These findings position the platform as a potentially transformative approach for next-generation radiopharmaceuticals, with the potential to improve efficacy, expand therapeutic opportunities, and create significant strategic value.
Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics for cancer. Powered by its proprietary Evans Blue (EB) technology platform, MTTI is advancing Ac-225 and Lu-177–based PRRT agents designed to enhance tumor targeting and retention, potentially enabling improved efficacy, lower radiation exposure, and earlier therapeutic responses.
For more information, please visit www.mtarget.com.
Media Contact: Chris Pak; Email: cpak@mtarget.com
FOR IMMEDIATE RELEASE
WEST CHESTER, Pa. (BUSINESS WIRE) — Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI’s medical team to advance clinical development of lead assets, EVA101 and EVA 102 and further progress the company’s radiopharmaceutical pipeline.
“My career goal in the TRT area has always been to improve care and outcomes for cancer patients. I believe MTTI is an exciting company with technology that is able to deliver on this goal. Our unique EvaThera platform has demonstrated the ability to enhance delivery of radiation to tumors, minimize off-target activity and reduce dosing requirements —collectively offering a potentially safer, more effective approach to TRT. I am thrilled to be supporting the team in leading EVA101 and EVA102 through the critical final stages of development,” said Danielle Meyrick, CMO of MTTI.
Dr. Chris Pak, President & CEO commented “MTTI is delighted to welcome Dr. Danielle Meyrick, an experienced clinician and executive. Her perspective and track record in TRT development are key complements to our team as we expedite advancement of our targeted radiotherapeutic pipeline.”
Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics (TRT). MTTI is committed to building value by translating innovative TRT to improve human healthcare. For more information: www.mtarget.com.
Chris Pak, Email: cpak@mtarget.com
FOR IMMEDIATE RELEASE
West Chester, PA, September 12, 2024, 6:01 am Eastern Standard Time (Business Wire) —Molecular Targeting Technologies, Inc. (MTTI) will update findings on its proprietary topical near-infrared fluorescent dye, CypH-11 (Cmetglo), at the World Molecular Imaging Conference (WMIC) meeting in Montreal from September 9-13 and at the Peritoneal Surface Oncology Group International (PSOGI) meeting in Lyon from September 26-28, 2024.
This convenient fast-acting technology* shows promise as an effective real-time tool for oncologists in fluorescence-guided surgery (FGS). This will allow clinicians to see small tumor residue and achieve a more complete resection of cancer in the abdominal cavity. We expect that Cmetglo may improve patient outcomes by avoiding unnecessary damage to normal tissue and increase progression-free survival of patients with peritoneal surface malignancies (PM).
Dr. Johnny Ong, MD, Associate Professor, Department of Sarcoma, Peritoneal and Rare Tumors, National Cancer Centre Singapore** commented: “One of the limitations of cytoreductive surgery (CRS) is the difficulty in distinguishing tumors from normal and scar tissues. Here, we performed ex vivo validation of patient tissues to evaluate the clinical utility of Cmetglo in detecting PM via topical administration. Preliminary analysis suggests that the best clinical utility of Cmetglo could be in patients with colorectal malignancy, with the possibility of expanding its use to other histological subtypes.”
Dr. Brian D Gray, SVP Research and Development noted: “MTTI’s Cmetglo makes the invisible visible. Tumor margins and metastases glow under near-infrared light. It can be a valuable addition to the surgeon’s’ armamentarium to achieve maximal cytoreduction during FGS.”
Dr. Seung Koo Lee, Assistant Professor of Cell Biology Research, in Radiology at Weill Cornell Medicine***, commented: “CypH-11 is a sprayable pH-responsive fluorogenic probe that exhibits minimal fluorescence at neutral pH; however, it fluoresces brightly in an acidic environment which is a universal signature of cancer cell proliferation. Its capability of detecting small-sized ovarian tumors was further demonstrated by the spray of CypH-11 in a disseminated high-grade serous ovarian cancer (HGSOC) model.”
Chris Pak, President & CEO of MTTI commented: This groundbreaking molecule builds on MTTI’s innovative legacy in targeted diagnostics and therapeutics. We’re pursuing its use in colorectal, ovarian, and brain cancers, adding value to patients, surgeons, and other stakeholders.”
Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics for rare cancers. MTTI is committed to building value by translating innovative radiopharmaceuticals to improve human health. For more information: www.mtarget.com.
Contact: Chris Pak, Email: cpak@mtarget.com
*This research is supported by the National Cancer Institute (NCI) for a SBIR phase II grant # R44CA275434 to MTTI.
** This research is also supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd and administered by National Health Innovation Centre (NHIC) under its Innovation to Industry (I2I) grant (NHIC Ref No.: NHIC-I2I-2306016) to National Cancer Centre Singapore. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not reflect the views of NHIC
***Weill Cornell Medicine and MTTI hold intellectual property and financial interests in Cmetglo technology under development by MTTI.
FOR IMMEDIATE RELEASE
September 11, 2024, 6:01 am Eastern Standard Time, West Chester, PA (Business Wire)
Molecular Targeting Technologies, Inc. (MTTI), is delighted to be working with Brookline Capital Markets at the 2nd Targeted Radionuclide Pharmaceuticals (TRPs) Supply Chain & Manufacturing Summit. They will present a special workshop “Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential” on September 24-26, 2024, in Boston, MA.
TRP industry experts will address commercial and pharmaceutical challenges and strategies as we bring actinium-225, lutetium-177, lead-212 and copper-67 isotopes to market, discussing: (i) Assessing Market Demand and Commercial Viability, (ii) Navigating Radiopharmaceutical Development Challenges, and (iii) Strategic Partnerships and Investment Opportunities.
Kemp Dolliver of Brookline Capital Markets stated: “The radiopharmaceutical sector is at the start of a long upcycle. We will explore market opportunities and the capital markets’ view of them.”
Chris Pak, founder and CEO of MTTI noted: “MTTI’s EB technology overcomes many challenges in TRPs today. Our long-acting patented platform provides 8 to 30-fold more uptake at the target compared to the standard TRPs. Both preclinical and clinical studies show better efficacy and medical economics with only 40% of the radiation dose. We’re excited to expose the broad TRP audience to our high value, long-acting EB platform.”
ABOUT The 2nd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit. This summit focuses on enhancing radiopharmaceutical production to keep pace with rapid innovation driven by substantial investments from pharmaceutical giants. Leading senior decision-makers from the radiopharmaceutical field will discuss critical topics such as isotope production, radiolabeling, quality control, regulatory considerations, and supply chain logistics. Amid challenges like key material scarcity, this forum offers valuable insights from leading companies to optimize manufacturing processes, ensure reliable supply, and accelerate clinical trials. For more information: https://ter.li/eigjvk
ABOUT Molecular Targeting Technologies, Inc. MTTI is a clinical-stage company developing innovative targeted radiotherapeutics for rare cancers with high unmet needs. MTTI’s pipeline includes: EBTATE® (ongoing studies in neuroendocrine [NET]; Hürthle cell thyroid [HTC], Nasopharyngeal [NPC] and small cell lung cancers) and EBRGDTM for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). For more information: https://mtarget.com
Contact:
Chris Pak, Email: cpak@mtarget.com;
Iwan Cleave, Email: info@hansonwade.com
FOR IMMEDIATE RELEASE
West Chester, PA, May 21, 2024, 6:01 am Eastern Standard Time (Business Wire)–Molecular Targeting Technologies, Inc. (MTTI), will update findings on both 177Lu-EBTATE clinical and 225Ac-EBTATE preclinical work during the 2024 SNMMI meeting in Toronto June 8-11 (exhibition booth #1819).
177Lu-EBTATE® an EvaThera drug, is the first patented long-acting peptide targeted radiotherapeutic drugs. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide payload. Evans blue in EBTATE binds to serum albumin, extending in vivo circulatory half-life and tumor residence time, enabling effective use of significantly lower radiopharmaceutical activity and fewer dosing cycles vs. the current standard of care (SOC). These benefits are also evident in recent studies of the 225Ac-EBTATE homolog.
Professor Zhaohui Zhu, MD, Peking Union Medical College Hospital, reflected “In our 3-year follow up on 30 patients* with metastatic neuroendocrine tumors (mNETs), 177Lu-EBTATE demonstrated good safety, with no nephro- or hepatoxicity and 86% disease control rate using 60% less radioactivity than 177Lu-DOTATATE. We observed low incidence of grade 3 hematoxicity (3.4% vs 15% of reported SOC) and no long-term nephrotoxicity of any grade.”
The study “Long acting 225Ac-EBTATE is highly efficacious against somatostatin receptor-2-positive small-cell lung cancer (SCLC)**” has been accepted for presentation at 2024 SNMMI. Professor Humphrey Fonge of the University of Saskatchewan commented, “225Ac-EBTATE (2x 30 kBq administered 10 days apart) was effective against SCLC with 80% complete remissions and 100% survival. Treatment yielded a 2-fold greater tumor growth inhibition when compared with 225Ac-DOTATATE, at 60% less administered radioactivity. Toxicity, as measured by body weight, blood counts, and chemistry showed that 225Ac-EBTATE was well tolerated at a highly effective dose. 225Ac-EBTATE shows great promise against SCLC.” Chris Pak, President & CEO of MTTI commented: “We are pleased to learn that 177Lu-EBTATE exhibited no safety concerns and was effective at a lower dose than SOC in mNET patients. We are also encouraged that 225Ac-EBTATE out-performed 225Ac-DOTATATE, providing a 2-fold greater tumor growth inhibition in preclinical findings using a much lower dose of radioactivity. We look forward to advancing our clinical trials with these radiotherapeutic drugs in small-cell lung and other cancers.”
Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics for rare cancers. MTTI is committed to building value by translating innovative radiopharmaceuticals to improve human health. For more information: www.mtarget.com.
Contact: Chris Pak, Email: cpak@mtarget.com
*Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics 2022; 12: 6437-6445
**The data will be presented in 2024 SNMMI. Fabrice Njotu, Humphrey Fonge et al. of the University of Saskatchewan, and Molecular Targeting Technologies, Inc.
FOR IMMEDIATE RELEASE
West Chester, PA, and Singapore, August 2, 2023 — Molecular Targeting Technologies, Inc. (MTTI), and its wholly owned subsidiary, Molecular Theranostic Center of Singapore (MTCS), announced the approval of a Clinical Trial Authorization (CTA) application by the Health Sciences Authority (HSA) of Singapore. The CTA enables a Phase IB/II, open-label study of the safety and efficacy of a 3-dose regimen of 177Lu-DOTA-EB-TATE (EBTATE) in patients with nasopharyngeal cancer (NPC) to be conducted at the National University Cancer Institute Singapore (NCIS) and the National University of Singapore (NUS).
Somatostatin receptor 2 (SSTR2) is found in 81% of primary, recurrent, and metastatic NPC patients. EBTATE, the first patented and only long-acting peptide receptor radionuclide therapy (PRRT) targeting SSTR2 receptors, binds reversibly to serum albumin, resulting in prolonged circulation half-life, increased tumor uptake and retention, and improved therapeutic outcome by delivering an 8-fold greater dose to the tumor compared to 177Lu-Dotatate. A recent three-year clinical trial follow-up* showed EBTATE was effective at controlling tumor and well tolerated without serious adverse events or nephrotoxicity.
NPC has a high prevalence with 133,354 new cases and 80,008 deaths in 2020**. While treatment options include surgery, chemotherapy and radiation therapy, there are no approved molecularly targeted therapies for NPC.
Professor Goh Boon Cher, MD, Deputy Director of NICS and NUS, stated “We are pleased to be collaborating with MTTI/MTCS to evaluate this novel treatment for SSTR2 expressing NPC. The study which will be conducted at our hospital will bring new hope for nasopharyngeal cancer patients.”
Dr. Chris Pak, President & CEO of MTTI and Chairman of MTCS, remarked: “The Evans Blue (EB)-albumin binding motif of EBTATE prolongs its circulation half-life and enhances tumor targeting. In preclinical and early clinical studies, EBTATE provided several advantages such as 8-fold uptake in tumor and lower administered radioactive dose versus first generation 177Lu-Dotatate in many cancers. We hope this groundbreaking treatment will be beneficial for nasopharyngeal cancer patients.”
Molecular Targeting Technologies, Inc. (MTTI). MTTI is a clinical-stage company developing innovative targeted radiotherapeutics for rare cancers with high unmet needs. MTTI’s products include: EBTATE (neuroendocrine tumors (“NET”); Hürthle thyroid cancer (HTC), and nasopharyngeal cancer (NPC); EBRGD for non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Contact : Chris Pak, Email: cpak@mtarget.com
* Jiang Y, Liu Q, Wang G, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE (EBTATE) in patients with metastatic neuroendocrine tumors. Theranostics. 2022;12(15):6437-6445.
** https://www.cancer.net/cancer-types/nasopharyngeal-cancer/statistics
